{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:55:15Z","timestamp":1770980115815,"version":"3.50.1"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EUREKA","award":["UNIVPM \u2013 Decreti Rettorali no. 740 July 2013 and no. 812 September 2013"],"award-info":[{"award-number":["UNIVPM \u2013 Decreti Rettorali no. 740 July 2013 and no. 812 September 2013"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0228509","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:43:10Z","timestamp":1582123390000},"page":"e0228509","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0507-5717","authenticated-orcid":true,"given":"Noemi","family":"D\u2019Atanasio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Capezzone de Joannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Di Sante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Mangano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosella","family":"Ombrato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Bartella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Magar\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Prati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Vignaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Paolo","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Tongiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"pone.0228509.ref001","unstructured":"WHO. Antimicrobial resistance: global report on surveillance 2014. 2014."},{"issue":"7","key":"pone.0228509.ref002","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/AAC.01103-16","article-title":"Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States","volume":"60","author":"P McGann","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0228509.ref003","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/675592","article-title":"Addressing the emergence and impact of multidrug-resistant gram-negative organisms: a critical focus for the next decade","volume":"35","author":"E Lautenbach","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"Suppl 1","key":"pone.0228509.ref004","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/319370","article-title":"Mechanisms of action of antimicrobials: focus on fluoroquinolones","volume":"32","author":"DC Hooper","year":"2001","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"pone.0228509.ref005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"LL Silver","year":"2011","journal-title":"Clinical microbiology reviews"},{"issue":"4","key":"pone.0228509.ref006","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1073\/pnas.77.4.1847","article-title":"DNA gyrase action involves the introduction of transient double-strand breaks into DNA","volume":"77","author":"K Mizuuchi","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"22","key":"pone.0228509.ref007","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1101\/gad.9.22.2859","article-title":"Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli","volume":"9","author":"EL Zechiedrich","year":"1995","journal-title":"Genes & development"},{"issue":"2","key":"pone.0228509.ref008","article-title":"DNA Topoisomerases","volume":"6","author":"NG Bush","year":"2015","journal-title":"EcoSal Plus"},{"issue":"8","key":"pone.0228509.ref009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"LS Redgrave","year":"2014","journal-title":"Trends in microbiology"},{"key":"pone.0228509.ref010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-199958002-00002","article-title":"Mode of action of fluoroquinolones","volume":"582","author":"DC Hooper","year":"1999","journal-title":"Drugs"},{"issue":"42","key":"pone.0228509.ref011","doi-asserted-by":"crossref","first-page":"27668","DOI":"10.1074\/jbc.273.42.27668","article-title":"The mechanism of inhibition of topoisomerase IV by quinolone antibacterials","volume":"273","author":"AB Khodursky","year":"1998","journal-title":"The Journal of biological chemistry"},{"issue":"12","key":"pone.0228509.ref012","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1073\/pnas.73.12.4474","article-title":"Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase","volume":"73","author":"M Gellert","year":"1976","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"pone.0228509.ref013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM195907162610307","article-title":"Novobiocin jaundice","volume":"261","author":"RP Cox","year":"1959","journal-title":"The New England journal of medicine"},{"issue":"1","key":"pone.0228509.ref014","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0924-8579(00)00192-8","article-title":"The fluoroquinolone antibacterials: past, present and future perspectives","volume":"16","author":"PC Appelbaum","year":"2000","journal-title":"International journal of antimicrobial agents"},{"key":"pone.0228509.ref015","unstructured":"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm500325.htm."},{"key":"pone.0228509.ref016","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"JJ Champoux","year":"2001","journal-title":"Annual review of biochemistry"},{"issue":"6","key":"pone.0228509.ref017","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"JC Wang","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 1","key":"pone.0228509.ref018","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1093\/clinids\/24.Supplement_1.S67","article-title":"Trends in bacterial resistance to fluoroquinolones","volume":"24","author":"JF Acar","year":"1997","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"7309","key":"pone.0228509.ref019","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"BD Bax","year":"2010","journal-title":"Nature"},{"issue":"19","key":"pone.0228509.ref020","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.bmcl.2013.07.013","article-title":"Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases","volume":"23","author":"TJ Miles","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"pone.0228509.ref021","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.00496-08","article-title":"Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases","volume":"52","author":"MT Black","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"pone.0228509.ref022","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm300690s","article-title":"Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile","volume":"55","author":"F Reck","year":"2012","journal-title":"J Med Chem"},{"issue":"5","key":"pone.0228509.ref023","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1128\/AAC.02778-13","article-title":"NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy","volume":"58","author":"TJ Dougherty","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pone.0228509.ref024","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens","volume":"60","author":"DJ Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0228509.ref025","article-title":"Virtual Screening Approach and Investigation of Structure Activity Relationships to Discover Novel Bacterial Topoisomerase Inhibitors (NBTIs) Targeting Gram-Positive and Gram-Negative Pathogens","author":"G Magaro","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"pone.0228509.ref026","unstructured":"Ombrato R MG, Garofalo B, Furlotti G, Mangano G, Capezzone De Joannon A., inventorNew antibacterial compounds.December 2017."},{"key":"pone.0228509.ref027","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility test for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA, USA; 2015."},{"key":"pone.0228509.ref028","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility testing of Anaerobic bacteria; Approved Standard-Eighth Edition. M11-A8. Clinical and Laboratory Standards Institute, Wayne, PA, USA; 2012."},{"key":"pone.0228509.ref029","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing. 25th informational supplement. Document M100-S25.: Clinical and Laboratory Standards Institute, Wayne, PA, USA; 2015."},{"key":"pone.0228509.ref030","first-page":"14","volume-title":"Clinical Microbiology Procedures Handbook second ed","author":"C Knapp","year":"1992"},{"issue":"1","key":"pone.0228509.ref031","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.04124-14","article-title":"In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria","volume":"59","author":"MD Huband","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0228509.ref032","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1471-2180-10-119","article-title":"In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations","volume":"10","author":"L Drago","year":"2010","journal-title":"BMC microbiology"},{"issue":"1\u20132","key":"pone.0228509.ref033","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1574-6968.1992.tb05303.x","article-title":"PCR amplification of streptococcal DNA using crude cell lysates","volume":"73","author":"WL Hynes","year":"1992","journal-title":"FEMS microbiology letters"},{"issue":"5","key":"pone.0228509.ref034","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"P Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0228509.ref035","first-page":"23","article-title":"A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry","volume":"29","author":"EA Dierks","year":"2001","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"pone.0228509.ref036","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3389\/fphar.2014.00203","article-title":"Early identification of hERG liability in drug discovery programs by automated patch clamp","volume":"5","author":"T Danker","year":"2014","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0228509.ref037","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0006-2952(98)00082-3","article-title":"Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents","volume":"56","author":"D Perrin","year":"1998","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"pone.0228509.ref038","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1271\/bbb.67.1944","article-title":"Cytotoxicity and DNA topoisomerase inhibitory activity of benz[f]indole-4,9-dione analogs","volume":"67","author":"HJ Park","year":"2003","journal-title":"Bioscience, biotechnology, and biochemistry"},{"issue":"12","key":"pone.0228509.ref039","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1073\/pnas.87.12.4776","article-title":"TolC, an Escherichia coli outer membrane protein required for hemolysin secretion","volume":"87","author":"C Wandersman","year":"1990","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"21","key":"pone.0228509.ref040","doi-asserted-by":"crossref","first-page":"6855","DOI":"10.1128\/JB.179.21.6855-6857.1997","article-title":"The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump","volume":"179","author":"L Sanchez","year":"1997","journal-title":"Journal of bacteriology"},{"issue":"1","key":"pone.0228509.ref041","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1128\/AAC.00715-09","article-title":"Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence","volume":"54","author":"E Padilla","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0228509.ref042","doi-asserted-by":"crossref","first-page":"e02100","DOI":"10.1128\/AAC.02100-16","article-title":"Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria","volume":"61","author":"C Charrier","year":"2017","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"pone.0228509.ref043","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.41.6.1281","article-title":"Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model","volume":"41","author":"AA Firsov","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"pone.0228509.ref044","unstructured":"Lorian V. In: Wilkins LW, editor. Antibiotics in laboratory medicine. Fourth ed1996."},{"issue":"9","key":"pone.0228509.ref045","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1128\/AAC.00571-15","article-title":"Insights into the mechanism of inhibition of novel bacterial topoisomerase inhibitors from characterization of resistant mutants of Staphylococcus aureus","volume":"59","author":"SD Lahiri","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0228509.ref046","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jac\/dks377","article-title":"Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae","volume":"68","author":"JM Rodriguez-Martinez","year":"2013","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"7","key":"pone.0228509.ref047","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/jac\/dks086","article-title":"Prevalence of the oqxAB gene complex in Klebsiella pneumoniae and Escherichia coli clinical isolates","volume":"67","author":"J Yuan","year":"2012","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"6","key":"pone.0228509.ref048","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1067\/mic.2001.119952","article-title":"National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001","volume":"29","author":"Centers for Disease Control and Prevention NNIS System","year":"2001","journal-title":"American journal of infection control"},{"key":"pone.0228509.ref049","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1086\/320184","article-title":"Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"322","author":"DJ Diekema","year":"2001","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"pone.0228509.ref050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1128\/CMR.3.1.46","article-title":"The life and times of the Enterococcus","volume":"3","author":"BE Murray","year":"1990","journal-title":"Clinical microbiology reviews"},{"issue":"3","key":"pone.0228509.ref051","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"AP Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"pone.0228509.ref052","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/529198","article-title":"Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clinical infectious diseases: an official publication of the","volume":"46","author":"LL Maragakis","year":"2008","journal-title":"Infectious Diseases Society of America"},{"key":"pone.0228509.ref053","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/s12879-015-1029-2","article-title":"Current and future antimicrobial treatment of gonorrhoea\u2014the rapidly evolving Neisseria gonorrhoeae continues to challenge","volume":"15","author":"M. Unemo","year":"2015","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0228509.ref054","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.44.1.186-189.2000","article-title":"Postantibiotic effects of grepafloxacin compared to those of five other agents against 12 gram-positive and -negative bacteria","volume":"44","author":"SK Spangler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0228509.ref055","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/jac\/31.6.881","article-title":"Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of meropenem","volume":"31","author":"I. Odenholt-Tornqvist","year":"1993","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"2","key":"pone.0228509.ref056","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.01208-12","article-title":"In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus","volume":"57","author":"VH Tam","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0228509.ref057","article-title":"AACNAp.","volume":"58","author":"TJ Dougherty","year":"2014","journal-title":"NBTI 5463 Is a Novel Bacterial Type II Topoisomerase Inhibitor withActivity against Gram-Negative Bacteria and In Vivo Efficacy"},{"issue":"8","key":"pone.0228509.ref058","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1128\/AAC.00619-16","article-title":"In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase","volume":"60","author":"CM Tan","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"pone.0228509.ref059","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/AAC.38.9.2014","article-title":"Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus","volume":"38","author":"H Ito","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0228509.ref060","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1128\/AAC.43.8.1845","article-title":"Activities of Trovafloxacin Compared with Those of Other Fluoroquinolones against Purified Topoisomerases and gyrA and grlA Mutants of Staphylococcus aureus","volume":"43","author":"TD Gootz","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pone.0228509.ref061","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1128\/AAC.50.4.1228-1237.2006","article-title":"In Vitro Characterization of the Antibacterial Spectrum of Novel Bacterial Type II Topoisomerase Inhibitors of the Aminobenzimidazole Class","volume":"50","author":"N Mani","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:44:03Z","timestamp":1582123443000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0228509"}},"subtitle":[],"editor":[{"given":"Prabagaran","family":"Narayanasamy","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0228509","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]}}}